Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity

Journal of Experimental Medicine

Volumn 215, Issue 3, 2018, Pages 859-876

  Hoves, Sabine ^a   Ooi, Chia Huey ^a,b   Wolter, Carsten ^a   Sade, Hadassah ^a   Bissinger, Stefan ^a   Schmittnaegel, Martina ^d   Ast, Oliver ^c   Giusti, Anna M ^c   Wartha, Katharina ^a,e   Runza, Valeria ^a   Xu, Wei ^c   Kienast, Yvonne ^a   Cannarile, Michael A ^a   Levitsky, Hyam ^c,f   Romagnoli, Solange ^a   De Palma, Michele ^d   Rüttinger, Dominik ^a   Ries, Carola H ^a  

^a ROCHE INNOVATION CENTER MUNICH   (Germany)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c Roche Innovation Center Zurich   (Switzerland)

^d EPFL   (Switzerland)

^e ACTELION PHARMACEUTICALS LTD   (Switzerland)

^f Juno Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; CHECKPOINT KINASE INHIBITOR; COLONY STIMULATING FACTOR 1 RECEPTOR; CYTOKINE RECEPTOR; TRANSCRIPTOME; UNCLASSIFIED DRUG; CD40 ANTIGEN; COLONY STIMULATING FACTOR RECEPTOR;

ARTICLE; CANCER GRAFT; CELL LYSATE; CELL REPROGRAMMING TECHNIQUE; COLORECTAL CARCINOMA; EX VIVO STUDY; GENE EXPRESSION PROFILING; HUMAN; IMMUNITY; INTRACELLULAR SIGNALING; MACROPHAGE ACTIVATION; MESOTHELIOMA; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR REJECTION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; C57BL MOUSE; CD8+ T LYMPHOCYTE; FEMALE; IMMUNOLOGY; INFLAMMATION; MACROPHAGE; METABOLISM; NEOPLASM; PATHOLOGY; PHENOTYPE;

ANIMALS; CD40 ANTIGENS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNITY; INFLAMMATION; MACROPHAGES; MICE, INBRED BALB C; MICE, INBRED C57BL; MODELS, BIOLOGICAL; NEOPLASMS; PHENOTYPE; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR;

EID: 85042861054     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20171440     Document Type: Article

References (70)

1. Baer, C., M.L. Squadrito, D. Laoui, D. Thompson, S.K. Hansen, A. Kiialainen, S. Hoves, C.H. Ries, C.H. Ooi, and M. De Palma. 2016. Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity. Nat. Cell Biol. 18:790-802. https ://doi .org /10 .1038 /ncb3371
2. Beatty, G.L., E.G. Chiorean, M.P. Fishman, B. Saboury, U.R. Teitelbaum, W. Sun, R.D. Huhn, W. Song, D. Li, L.L. Sharp, et al. 2011. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 331:1612-1616. https ://doi .org /10 .1126 / science .1198443
3. Beatty, G.L., D.A. Torigian, E.G. Chiorean, B. Saboury, A. Brothers, A. Alavi, A.B. Troxel, W. Sun, U.R. Teitelbaum, R.H. Vonderheide, and P.J. O'Dwyer. 2013. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin. Cancer Res. 19:6286-6295. https ://doi .org /10 .1158 /1078-0432 .CCR-13-1320
4. Biswas, S.K., and A. Mantovani. 2010. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11:889-896. https ://doi .org /10 .1038 /ni .1937
5. Bouchlaka, M.N., G.D. Sckisel, M. Chen, A. Mirsoian, A.E. Zamora, E. Maverakis, D.E. Wilkins, K.L. Alderson, H.H. Hsiao, J.M. Weiss, et al. 2013. Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy. J. Exp. Med. 210:2223-2237. https ://doi .org /10.1084 /jem .20131219
6. Bovenschen, N., and J.A. Kummer. 2010. Orphan granzymes find a home. Immunol. Rev. 235:117-127. https ://doi .org /10 .1111 /j .0105-2896 .2010.00889 .x
7. Buhtoiarov, I.N., H.D. Lum, G. Berke, P.M. Sondel, and A.L. Rakhmilevich. 2006. Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects. J. Immunol. 176:309-318. https ://doi .org /10 .4049 /jimmunol .176 .1 .309
8. Byrne, K.T., N.H. Leisenring, D.L. Bajor, and R.H. Vonderheide. 2016. CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy. J. Immunol. 197:179-187. https ://doi .org /10 .4049 /jimmunol .1600146
9. Chen, T., and C. Srinivas. 2015. Group sparsity model for stain unmixing in brightfield multiplex immunohistochemistry images. Comput. Med. Imaging Graph. 46:30-39. https ://doi .org /10 .1016 /j .compmedimag .2015 .04 .001
10. Coussens, L.M., L. Zitvogel, and A.K. Palucka. 2013. Neutralizing tumorpromoting chronic inflammation: a magic bullet? Science. 339:286-291. https ://doi .org /10 .1126 /science .1232227
11. Dahan, R., B.C. Barnhart, F. Li, A.P. Yamniuk, A.J. Korman, and J.V. Ravetch. 2016. Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement. Cancer Cell. 29:820-831. https ://doi .org /10 .1016 /j .ccell .2016 .05 .001
12. De Henau, O., M. Rausch, D. Winkler, L.F. Campesato, C. Liu, D.H. Cymerman, S. Budhu, A. Ghosh, M. Pink, J. Tchaicha, et al. 2016. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature. 539:443-447. https ://doi .org /10 .1038/nature20554
13. Eissler, N., Y. Mao, D. Brodin, P. Reuterswärd, H. Andersson Svahn, J.I. Johnsen, R. Kiessling, and P. Kogner. 2016. Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade. OncoImmunology. 5:e1232222. https ://doi .org /10 .1080 /2162402X .2016 .1232222
14. Elgueta, R., M.J. Benson, V.C. de Vries, A. Wasiuk, Y. Guo, and R.J. Noelle. 2009. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev. 229:152-172. https ://doi .org /10.1111 /j .1600-065X .2009 .00782 .x
15. Eliopoulos, A.G., and L.S. Young. 2004. The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr. Opin. Pharmacol. 4:360-367. https ://doi .org /10 .1016 /j .coph .2004 .02 .008
16. Fonsatti, E., M. Maio, M. Altomonte, and P. Hersey. 2010. Biology and clinical applications of CD40 in cancer treatment. Semin. Oncol. 37:517-523. https ://doi .org /10 .1053 /j .seminoncol .2010 .09 .002
17. Gajewski, T.F., H. Schreiber, and Y.X. Fu. 2013. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14:1014-1022. https ://doi .org /10 .1038 /ni .2703
18. Gentleman, R., and R. Ihaka. 2017. The R Stats Package. Documentation for package 'stats' version 3.5.0. https ://stat .ethz .ch /R-manual /R-devel /library /stats /html /00Index .html
19. Gordon, S., and F.O. Martinez. 2010. Alternative activation of macrophages: mechanism and functions. Immunity. 32:593-604. https ://doi .org /10 .1016 /j .immuni .2010 .05 .007
20. Grewal, I.S., and R.A. Flavell. 1998. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16:111-135. https ://doi .org /10 .1146 / annurev .immunol .16 .1 .111
21. Guiducci, C., A.P. Vicari, S. Sangaletti, G. Trinchieri, and M.P. Colombo. 2005. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res. 65:3437-3446. https ://doi .org /10 .1158 /0008-5472 .CAN-04-4262
22. He, H., J.J. Mack, E. Güç, C.M. Warren, M.L. Squadrito, W.W. Kilarski, C. Baer, R.D. Freshman, A.I. McDonald, S. Ziyad, et al. 2016. Perivascular Macrophages Limit Permeability. Arterioscler. Thromb. Vasc. Biol. 36:2203-2212. https ://doi .org /10 .1161 /ATV BAHA .116 .307592
23. Herbst, R.S., J.C. Soria, M. Kowanetz, G.D. Fine, O. Hamid, M.S. Gordon, J.A. Sosman, D.F. McDermott, J.D. Powderly, S.N. Gettinger, et al. 2014. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 515:563-567. https ://doi .org /10 .1038 /nature14011
24. Hodi, F.S., S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, J.B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J.C. Hassel, et al. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363:711-723. https ://doi .org /10 .1056 / NEJMoa1003466
25. Holmgaard, R.B., A. Brachfeld, B. Gasmi, D.R. Jones, M. Mattar, T. Doman, M. Murphy, D. Schaer, J.D. Wolchok, and T. Merghoub. 2016. Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy. OncoImmunology. 5:e1151595. https :// doi .org /10 .1080 /2162402X .2016 .1151595
26. Hu, X., and L.B. Ivashkiv. 2009. Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity. 31:539-550. https ://doi .org /10 .1016 /j .immuni .2009.09 .002
27. Jenabian, M.A., M. Patel, I. Kema, K. Vyboh, C. Kanagaratham, D. Radzioch, P. Thébault, R. Lapointe, N. Gilmore, P. Ancuta, et al. 2014. Soluble CD40-ligand (sCD40L, sCD154) plays an immunosuppressive role via regulatory T cell expansion in HIV infection. Clin. Exp. Immunol. 178:102-111. https ://doi .org /10 .1111 /cei .12396
28. Kaneda, M.M., K.S. Messer, N. Ralainirina, H. Li, C.J. Leem, S. Gorjestani, G. Woo, A.V. Nguyen, C.C. Figueiredo, P. Foubert, et al. 2016. PI3Kγ is a molecular switch that controls immune suppression. Nature. 539:437-442. https ://doi .org /10 .1038 /nature19834
29. Kulkarni, M.M. 2011. Digital multiplexed gene expression analysis using the NanoString nCounter system. Curr. Protoc. Mol. Biol. Chapter 25:10
30. Langlais, D., L.B. Barreiro, and P. Gros. 2016. The macrophage IRF8/IRF1 regulome is required for protection against infections and is associated with chronic inflammation. J. Exp. Med. 213:585-603. https ://doi .org /10 .1084 /jem .20151764
31. Li, F., and J.V. Ravetch. 2011. Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science. 333:1030-1034. https ://doi .org /10 .1126 /science .1206954
32. Lin, E.Y., A.V. Nguyen, R.G. Russell, and J.W. Pollard. 2001. Colonystimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193:727-740. https ://doi .org /10 .1084 /jem .193 .6 .727
33. MacDonald, K.P., J.S. Palmer, S. Cronau, E. Seppanen, S. Olver, N.C. Raffelt, R. Kuns, A.R. Pettit, A. Clouston, B. Wainwright, et al. 2010. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue-and tumor-associated macrophages but does not inhibit inflammation. Blood. 116:3955-3963. https ://doi .org /10 .1182 /blood-2010-02-266296
34. Mantovani, A., F. Marchesi, A. Malesci, L. Laghi, and P. Allavena. 2017. Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol. 14:399-416. https ://doi .org /10 .1038 /nrclinonc .2016.217
35. Marigo, I., S. Zilio, G. Desantis, B. Mlecnik, A.H. Agnellini, S. Ugel, M.S. Sasso, J.E. Qualls, F. Kratochvill, P. Zanovello, et al. 2016. T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells. Cancer Cell. 30:651. https ://doi .org /10 .1016 /j .ccell .2016 .09 .009
36. Martinez, F.O., S. Gordon, M. Locati, and A. Mantovani. 2006. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J. Immunol. 177:7303-7311. https ://doi .org /10 .4049 /jimmunol .177 .10 .7303
37. Martinez, F.O., L. Helming, R. Milde, A. Varin, B.N. Melgert, C. Draijer, B. Thomas, M. Fabbri, A. Crawshaw, L.P. Ho, et al. 2013. Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences. Blood. 121:e57-e69. https :// doi .org /10 .1182 /blood-2012-06-436212
38. Mok, S., R.C. Koya, C. Tsui, J. Xu, L. Robert, L. Wu, T. Graeber, B.L. West, G. Bollag, and A. Ribas. 2014. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. 74:153-161. https ://doi .org /10 .1158 /0008-5472 .CAN-13-1816
39. Murphy, T.L., R. Tussiwand, and K.M. Murphy. 2013. Specificity through cooperation: BATF-IRF interactions control immune-regulatory networks. Nat. Rev. Immunol. 13:499-509. https ://doi .org /10 .1038 / nri3470
40. Nakajima, A., T. Kodama, S. Morimoto, M. Azuma, K. Takeda, H. Oshima, S. Yoshino, H. Yagita, and K. Okumura. 1998. Antitumor effect of CD40 ligand: elicitation of local and systemic antitumor responses by IL-12 and B7. J. Immunol. 161:1901-1907
41. Perry, C.J., A.R. Muñoz-Rojas, K.M. Meeth, L.N. Kellman, R.A. Amezquita, D. Thakral, V.Y. Du, J.X. Wang, W. Damsky, A.L. Kuhlmann, J.W. Sher, et al. 2018. Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity. J. Exp. Med. https ://doi .org /10.1084 /jem .20171435
42. Pyonteck, S.M., L. Akkari, A.J. Schuhmacher, R.L. Bowman, L. Sevenich, D.F. Quail, O.C. Olson, M.L. Quick, J.T. Huse, V. Teijeiro, et al. 2013. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19:1264-1272. https ://doi .org /10 .1038 /nm .3337
43. Rakhmilevich, A.L., K.L. Alderson, and P.M. Sondel. 2012. T-cell-independent antitumor effects of CD40 ligation. Int. Rev. Immunol. 31:267-278. https ://doi .org /10 .3109 /08830185 .2012 .698337
44. Richman, L.P., and R.H. Vonderheide. 2014. Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer. Cancer Immunol. Res. 2:19-26. https ://doi .org /10 .1158 /2326-6066 .CIR-13-0152
45. Ries, C.H., M.A. Cannarile, S. Hoves, J. Benz, K. Wartha, V. Runza, F. Rey-Giraud, L.P. Pradel, F. Feuerhake, I. Klaman, et al. 2014. Targeting tumorassociated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 25:846-859. https ://doi .org /10 .1016 /j .ccr .2014 .05 .016
46. Ries, C.H., S. Hoves, M.A. Cannarile, and D. Rüttinger. 2015. CSF-1/ CSF-1R targeting agents in clinical development for cancer therapy. Curr. Opin. Pharmacol. 23:45-51. https ://doi .org /10 .1016 /j .coph .2015.05 .008
47. Rizvi, N.A., M.D. Hellmann, A. Snyder, P. Kvistborg, V. Makarov, J.J. Havel, W. Lee, J. Yuan, P. Wong, T.S. Ho, et al. 2015. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 348:124-128. https ://doi .org /10 .1126 /science .aaa1348
48. Ruffell, B., and L.M. Coussens. 2015. Macrophages and therapeutic resistance in cancer. Cancer Cell. 27:462-472. https ://doi .org /10 .1016 /j .ccell .2015 .02 .015
49. Ruffell, B., D. Chang-Strachan, V. Chan, A. Rosenbusch, C.M. Ho, N. Pryer, D. Daniel, E.S. Hwang, H.S. Rugo, and L.M. Coussens. 2014. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell. 26:623-637. https ://doi .org /10 .1016 /j .ccell .2014 .09 .006
50. Sandin, L.C., A. Orlova, E. Gustafsson, P. Ellmark, V. Tolmachev, T.H. Tötterman, and S.M. Mangsbo. 2014. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer. Cancer Immunol. Res. 2:80-90. https ://doi .org /10 .1158 /2326-6066 .CIR-13-0067
51. Sandmann, T., S.K. Kummerfeld, R. Gentleman, and R. Bourgon. 2014. gCMAP: user-friendly connectivity mapping with R. Bioinformatics. 30:127-128. https ://doi .org /10 .1093 /bioinformatics /btt592
52. Scheu, S., S. Ali, C. Ruland, V. Arolt, and J. Alferink. 2017. The C-C Chemokines CCL17 and CCL22 and Their Receptor CCR4 in CNS Autoimmunity. Int. J. Mol. Sci. 18:2306. https ://doi .org /10 .3390 / ijms18112306
53. Schlothauer, T., S. Herter, C.F. Koller, S. Grau-Richards, V. Steinhart, C. Spick, M. Kubbies, C. Klein, P. Umaña, and E. Mössner. 2016. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Protein Eng. Des. Sel. 29:457-466. https ://doi .org /10 .1093 /protein /gzw040
54. Schmieder, A., J. Michel, K. Schönhaar, S. Goerdt, and K. Schledzewski. 2012. Differentiation and gene expression profile of tumor-associated macrophages. Semin. Cancer Biol. 22:289-297. https ://doi .org /10 .1016/j .semcancer .2012 .02 .002
55. Schroder, K., P.J. Hertzog, T. Ravasi, and D.A. Hume. 2004. Interferongamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 75:163-189. https ://doi .org /10 .1189 /jlb .0603252
56. Sharma, P., and J.P. Allison. 2015. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 161:205-214. https ://doi .org /10 .1016 /j .cell .2015 .03 .030
57. Singh-Jasuja, H., A. Thiolat, M. Ribon, M.C. Boissier, N. Bessis, H.G. Rammensee, and P. Decker. 2013. The mouse dendritic cell marker CD11c is down-regulated upon cell activation through Toll-like receptor triggering. Immunobiology. 218:28-39. https ://doi .org /10 .1016/j .imbio .2012 .01 .021
58. Stanley, E.R., and V. Chitu. 2014. CSF-1 receptor signaling in myeloid cells. Cold Spring Harb. Perspect. Biol. 6:a021857. https ://doi .org /10 .1101 / cshperspect .a021857
59. Subramanian, A., P. Tamayo, V.K. Mootha, S. Mukherjee, B.L. Ebert, M.A. Gillette, A. Paulovich, S.L. Pomeroy, T.R. Golub, E.S. Lander, and J.P. Mesirov. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA. 102:15545-15550. https ://doi .org /10 .1073 /pnas .0506580102
60. Suttles, J., and R.D. Stout. 2009. Macrophage CD40 signaling: a pivotal regulator of disease protection and pathogenesis. Semin. Immunol. 21:257-264. https ://doi .org /10 .1016 /j .smim .2009 .05 .011
61. Tamura, T., and K. Ozato. 2002. ICS BP/IRF-8: its regulatory roles in the development of myeloid cells. J. Interferon Cytokine Res. 22:145-152. https ://doi .org /10 .1089 /107999002753452755
62. Topalian, S.L., C.G. Drake, and D.M. Pardoll. 2015. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 27:450-461. https ://doi .org /10 .1016 /j .ccell .2015 .03 .001
63. Tumeh, P.C., C.L. Harview, J.H. Yearley, I.P. Shintaku, E.J. Taylor, L. Robert, B. Chmielowski, M. Spasic, G. Henry, V. Ciobanu, et al. 2014. PD-1blockade induces responses by inhibiting adaptive immune resistance. Nature. 515:568-571. https ://doi .org /10 .1038 /nature13954
64. Tutt, A.L., L. O'Brien, A. Hussain, G.R. Crowther, R.R. French, and M.J. Glennie. 2002. T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J. Immunol. 168:2720-2728. https :// doi .org /10 .4049 /jimmunol .168 .6 .2720
65. van der Sluis, T.C., M. Sluijter, S. van Duikeren, B.L. West, C.J. Melief, R. Arens, S.H. van der Burg, and T. van Hall. 2015. Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression. Cancer Immunol. Res. 3:1042-1051. https ://doi .org /10 .1158 /2326-6066 .CIR-15-0052
66. Vonderheide, R.H., and M.J. Glennie. 2013. Agonistic CD40 antibodies and cancer therapy. Clin. Cancer Res. 19:1035-1043. https ://doi .org /10 .1158/1078-0432 .CCR-12-2064
67. Wang, Q., and J. Liu. 2016. Regulation and Immune Function of IL-27. Adv. Exp. Med. Biol. 941:191-211. https ://doi .org /10 .1007 /978-94-024-0921-5 _9
68. Wiehagen, K.R., N.M. Girgis, D.H. Yamada, A.A. Smith, S.R. Chan, I.S. Grewal, M. Quigley, and R.I. Verona. 2017. Combination of CD40 agonism and CSF-1R blockade reconditions tumor-associated macrophages and drives potent antitumor immunity. Cancer Immunol. Res. 5:1109-1121; epub ahead of print. https ://doi .org /10 .1158 /2326-6066 .CIR-17-0258
69. Zhang, Q.W., L. Liu, C.Y. Gong, H.S. Shi, Y.H. Zeng, X.Z. Wang, Y.W. Zhao, and Y.Q. Wei. 2012. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One. 7:e50946. https ://doi .org /10 .1371 /journal .pone .0050946
70. Zhu, Y., B.L. Knolhoff, M.A. Meyer, T.M. Nywening, B.L. West, J. Luo, A. Wang-Gillam, S.P. Goedegebuure, D.C. Linehan, and D.G. DeNardo. 2014. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 74:5057-5069. https ://doi .org /10 .1158/0008-5472 .CAN-13-3723